AngioWaveNet vs AVIEW LCS
AI Verdict
Choose AngioWaveNet if…
Choose AngioWaveNet if your cardiac catheterization laboratory requires real-time, AI-powered enhancement of fluoroscopic angiograms to improve the visualization of blood vessels and anatomical structures during interventional procedures. This tool is ideal for cath labs seeking to integrate a vendor-agnostic solution that seamlessly enhances existing imaging workflows for clearer diagnostic and interventional guidance.
View AngioWaveNet →Choose AVIEW LCS if…
Choose AVIEW LCS if your radiology department or lung cancer screening program needs a comprehensive AI solution for automated detection and analysis of lung nodules, coupled with integrated assessment of COPD and coronary artery calcification from low-dose CT scans. This platform is best suited for facilities aiming to streamline cardiopulmonary assessment workflows, enhance diagnostic accuracy with automated reporting, and track nodule changes over time.
View AVIEW LCS →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AngioWaveNet | AVIEW LCS |
|---|---|---|
| Pricing | Pricing options include annual software licensing or subscription-based access, tailored to cath lab volume and hospital needs. custom packages are available. | Contact for pricing |
| Deployment | Cloud-based or on-premise/servers | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TieBoth tools emphasize seamless integration into existing clinical workflows and aim to streamline processes. AngioWaveNet highlights its vendor-agnostic compatibility and minimal training requirements. AVIEW LCS focuses on fully automatic analysis, comprehensive report generation, and integration with PACS/RIS to optimize radiology workflows. Without direct user experience comparisons, both demonstrate strong usability features.
Clinical Value
AVIEW LCSAVIEW LCS offers broader clinical value by providing integrated, multi-disease assessment for lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan. This comprehensive analysis can lead to more holistic patient assessments and earlier detection of comorbidities. AngioWaveNet, while critical for cardiac catheterization, focuses on enhancing vessel visualization for a specific procedure.
Pricing & Value
AngioWaveNetAngioWaveNet provides more transparency regarding its pricing model, offering flexible options such as annual software licensing or subscription-based access tailored to hospital needs. AVIEW LCS, in contrast, states 'contact for pricing,' which offers less immediate insight into its cost structure. This transparency gives Tool A an edge in perceived value.
Enterprise Readiness
AVIEW LCSBoth tools are FDA-cleared and HIPAA compliant, essential for healthcare enterprises. However, AVIEW LCS offers a wider array of deployment options, including cloud, hybrid, local dedicated hardware, and local virtualized solutions, providing greater flexibility for diverse IT infrastructures. Additionally, Tool B explicitly states it 'has_baa' (Business Associate Agreement), which is a critical component for enterprise data security and compliance in healthcare.
Innovation
AVIEW LCSAVIEW LCS's ability to perform integrated, multi-disease analysis (lung cancer, COPD, and coronary artery calcification) from a single low-dose CT scan represents a more comprehensive and potentially transformative innovation in diagnostic workflows. While AngioWaveNet's AI-powered spatiotemporal enhancement is valuable for improving visualization in angiography, AVIEW LCS offers broader diagnostic utility and efficiency gains across multiple pathologies.
Support & Docs
AngioWaveNetAngioWaveNet explicitly details its comprehensive support, including installation assistance, staff training, and access to ongoing updates and clinical resources, along with minimal training requirements. While AVIEW LCS highlights automated reporting and adherence to standards, it lacks similarly explicit statements about the breadth of its support and documentation for implementation and ongoing use from the vendor itself.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AngioWaveNet | AVIEW LCS |
|---|---|---|
| Tool Name | AngioWaveNet | AVIEW LCS |
| Company | Angiowave Imaging | Coreline Soft Co. |
| Description | FDA-cleared AI software that enhances fluoroscopic angiograms for improved vessel visualization in cardiac catheterization laboratories, integrating with existing Cath lab workflows. | AI-powered solution for the detection and analysis of lung nodules. The AVIEW LCS Plus platform provides integrated, fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan, enhancing diagnostic accuracy and streamlining radiology workflows. |
| Primary Focus | Improved vessel visualization in fluoroscopic angiograms | Automated lung nodule detection and analysis, lung cancer screening, COPD, and coronary artery calcification |
| Key Features (Examples) | AI-powered Spatiotemporal Enhancement Processing (STEPu2122); Improved vessel visualization; Integrates with existing Cath lab workflows; Compatible with any fluoroscopic angiography system (vendor-agnostic) | Automated lung nodule detection and analysis; Lung-RADS classification and reporting; Nodule volume quantification and 3D segmentation; Emphysema quantification (LAA index); Coronary Artery Calcification (CAC) scoring |
| Specialties | Cardiology, Interventional Radiology, Vascular Surgery | Cardiology, Oncology, Pulmonology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring AngioWaveNet and AVIEW LCS.